Welcome to our dedicated page for EMBI news (Ticker: EMBI), a resource for investors and traders seeking the latest updates and insights on EMBI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EMBI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EMBI's position in the market.
Skye Bioscience (OTCQB: SKYE) announced the appointment of cannabinoid experts Giovanni Appendino, PhD, and Eduardo Muñoz, MD, PhD, to its scientific advisory board. CEO Punit Dhillon emphasized the significance of their expertise in advancing cannabinoid-based medicines. Dr. Appendino brings over 40 years of research experience, while Dr. Muñoz has significant expertise in cannabinoid pharmacology and inflammation. Their contributions aim to enhance Skye's pipeline, particularly its lead molecule targeting glaucoma, which has shown promise in preclinical studies.
Skye Bioscience, Inc. (OTCQB: SKYE) announced that CEO Punit Dhillon will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 09, 2021, at 7:00 AM EST. The company focuses on developing synthetic cannabinoid-derived molecules to treat glaucoma and other unmet medical needs. The presentation will be available on Skye's investor relations website. Skye's lead molecule shows potential in lowering intraocular pressure in glaucoma patients, offering a new therapeutic class.
Skye Bioscience, Inc. (OTCQB: SKYE) announced participation in three investment events in February 2021. CEO Punit Dhillon will present at the Small-Cap Growth Investor Conference on February 4 at 3:30 PM EST. He will also present at the Money Show February Virtual Expo on February 18 at 11:20 AM EST. VP Karam Takhar will present at the Benzinga Cannabis Capital Conference on February 25 at 10:40 AM EST. These presentations will provide insights into their innovative cannabinoid-derived therapies targeting glaucoma and other unmet medical needs.
